Summary of the Conference Call for Jianyou Co., Ltd. Industry and Company Overview - Jianyou Co., Ltd. is a leading integrated player in the heparin raw materials and formulations industry, benefiting from a stabilized recovery in heparin raw material prices and solidifying profitability in traditional business segments [2][5][6]. Core Insights and Arguments - **High-end Injection Export Growth**: The high-end injection segment is identified as the second growth engine for Jianyou. The approval of Enoxaparin formulations in the US and European markets has led to rapid growth, with 82 US-approved varieties expected by the end of 2024 [2][6]. - **Expansion in Non-Heparin Products**: Jianyou is expanding its product pipeline in the non-heparin sector, averaging about 10 new ANDA varieties annually. The company is positioned to capture a larger market share, with significant growth potential compared to leading companies like Hikma [2][7]. - **Cost Advantages**: Chinese companies, including Jianyou, have a significant advantage in comprehensive manufacturing costs, which is expected to lead to higher profitability levels as they catch up with competitors like Hikma [2][7]. - **Biologics and Biosimilars Strategy**: Jianyou is strategically positioning itself in the biosimilars and innovative biologics sectors, leveraging its injection export resources. The US biosimilars market is projected to exceed $40 billion by 2027, presenting substantial growth opportunities [2][9]. - **Future Profitability Expectations**: The company is projected to achieve a net profit of approximately 1 billion yuan in 2025, supported by clear international growth potential in high-end formulations and favorable industry policies [3][10]. Additional Important Points - **Historical Context and Growth Model**: Jianyou has a rich history dating back to 1991, with a proven growth model and core competencies that have been validated over time. The current stock price is at a historical low, suggesting a potential investment opportunity [4]. - **Integrated Business Model**: The company has established a comprehensive business model that encompasses research, production, and sales in the heparin raw materials sector, which has solidified its market position [5]. - **Market Penetration Strategy**: Jianyou has successfully established a local marketing system in the US through strategic acquisitions, enhancing its brand influence and market share [6]. This summary encapsulates the key points discussed in the conference call, highlighting Jianyou Co., Ltd.'s strategic positioning, growth potential, and market dynamics.

Summary of Key Points from the Conference Call Company Overview - **Company**: 健友股份 (Jianyou Co., Ltd.) - **Industry**: Biopharmaceuticals, specifically focusing on biosimilars and large molecule drugs Core Insights and Arguments - **Market Entry Barriers**: The exemption of biosimilars from clinical trials does not significantly lower market entry barriers. Instead, it raises requirements for R&D processes, impurity profiles, and production stability, benefiting large companies with strong technical capabilities while posing challenges for small and medium enterprises [2][5] - **Revenue Growth**: In the first half of 2025, overseas heparin revenue grew approximately 10% outside Europe and the U.S., while the U.S. market remained flat. Non-heparin products saw a growth of about 25%, with large molecule products contributing significantly [2][5] - **Tariff Impact**: The new U.S. tariff policy primarily targets Europe, with limited impact on traditional textile pharmaceutical companies in China and India, as the U.S. only imposes tariffs on Chinese pharmaceutical formulations, which are relatively few [2][5] - **Future Plans**: The company plans to introduce new large molecule pipelines in the second half of the year, with expectations for significant progress in 2026. An insulin project has been submitted for approval, with anticipated launches in 2026 [2][6] - **Revenue Projections**: The company expects to achieve revenues of $120-130 million in 2025, $300 million in 2026, and a target of $500 million in 2027, although commercialization timelines may need adjustments [2][7] Additional Important Content - **Sales Team Expansion**: The marketing team grew by 60% in the first half of the year, with increased sales expenses due to a shift from a regional to a national and regional combined approach, ensuring targeted output [4][12] - **R&D Investment**: The company plans to keep R&D expenses within 4.5 billion RMB over the next three years, focusing on both small and large molecule drug development [4][21] - **Market Strategy in Europe**: The company aims to establish a sales team of 20-30 people in Europe, currently at 6-7, focusing on major markets like Italy, France, the UK, and Germany, with expectations for significant contributions by 2027 [13][14] - **Collaboration in Latin America and the Middle East**: The company prefers collaborative approaches for market expansion in these regions, leveraging local resources for sales and marketing [15][16] - **Profit Margin Expectations**: Gross margins for large molecules are significantly higher (70%-90%) compared to small molecules (40%-50%), indicating a greater profit potential in the large molecule segment [23] Conclusion - **Strategic Outlook**: The company maintains a stable development strategy, with expectations for growth in both small and large molecule sectors. The focus on biosimilars and international collaboration is seen as crucial for future success [26][27]

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, but showed significant improvement in the second quarter, driven by its biopharmaceutical business and export growth in formulations [1][2]. Financial Performance - In 1H25, the company's revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 1.98 billion, 286 million, and 260 million yuan, respectively, representing year-on-year declines of 7.60%, 29.32%, and 29.46% [1]. - For Q2 2025, the revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 1.095 billion, 202 million, and 185 million yuan, showing year-on-year declines of 3.84%, 11.53%, and 6.36%, but a quarter-on-quarter improvement of 24%, 138%, and 145% respectively [1][2]. Business Segments - The raw material drug business faced challenges, with revenue declining by 45% year-on-year to 291 million yuan in 1H25, reducing its revenue contribution to 15% from 25% in 1H24 [2]. - The formulation segment showed stable growth, with revenue of 1.659 billion yuan in 1H25, up 7% year-on-year, driven by strong export performance, particularly in the U.S. market, which generated 1.137 billion yuan, a 20% increase year-on-year [3]. - The company has received over 100 overseas approvals and is expanding its pipeline in the European market, aiming to replicate U.S. growth [3]. Biologics Development - The company is building a product matrix in biosimilars, with approvals for adalimumab, liraglutide, and paclitaxel biosimilars, and expects to introduce more potential products [3]. - The collaboration with Tonghua Dongbao on insulin products is anticipated to yield approvals starting in 2026 [3]. Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders of 1.024 billion, 1.327 billion, and 1.650 billion yuan for 2025-2027, representing year-on-year growth of 24%, 30%, and 24% respectively [4]. - The estimated EPS for the same period is 0.63, 0.82, and 1.02 yuan [4]. - A target price of 17.34 yuan is set, based on a 2025 PE of 27.37x, reflecting a 20% discount to the average PE of comparable companies [4].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has approved a stock repurchase plan with a total fund amount between RMB 20 million and RMB 40 million, with a maximum repurchase price of RMB 18.75 per share [2] - The repurchased shares will be used for employee stock ownership plans or equity incentives, and the implementation period is within 12 months from the approval date [2] - As of August 31, 2025, the company has repurchased a total of 880,000 shares, accounting for 0.05% of the total share capital, with a total payment of RMB 10.2207 million [3] Group 2 - The company will comply with relevant regulations and guidelines during the repurchase period and will make repurchase decisions based on market conditions [5] - The company is committed to timely information disclosure regarding the progress of the stock repurchase [5]

债券代码：113579 债券简称：健友转债 | | | 本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万 元（含），本次回购股份的价格不超过 18.75 元/股（含），本次回购的股份用于 员工持股计划或股权激励，回购股份实施期限为自公司股东大会审议通过本次回 购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 29 日披露的《健 友股份关于以集中竞价交易方式回购股份的预案》（公告编号：2025-028）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 8 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 88 万股，已回购股份占公司总股本的比例为 0.05%，成交最 低价为 11.58 元/股，成交最高价为 11.66 元/股，支付的总金额为人民币 1,022.07 万元（不含交易费用及印花税）。 南京健友生化制药股 ...

Group 1 - The company, Jianyou Co., Ltd. (603707.SH), has announced a share buyback program, having repurchased a total of 880,000 shares as of August 31, 2025 [1] - The repurchased shares account for 0.05% of the company's total share capital [1] - The total amount paid for the repurchased shares is approximately RMB 10.22 million, excluding transaction fees and stamp duty [1] Group 2 - The shares were repurchased through the Shanghai Stock Exchange trading system via centralized bidding [1] - The lowest transaction price for the repurchased shares was RMB 11.58 per share, while the highest was RMB 11.66 per share [1]

Investment Rating - The investment rating for the company is "Recommended" [1][8] Core Views - The company is experiencing rapid growth in its U.S. formulation segment, while its biosimilars are entering a period of significant market release [1][7] - The company reported a revenue of 1.98 billion yuan for the first half of 2025, a year-on-year decrease of 7.6%, and a net profit of 286 million yuan, down 29.32% year-on-year, which was slightly below previous expectations [3][7] - The company is focusing on expanding its biosimilar pipeline and has received multiple approvals from the U.S. FDA and the National Medical Products Administration of China [7][8] Financial Summary - Revenue projections for the company are as follows: 3.93 billion yuan in 2023, 3.92 billion yuan in 2024, 4.29 billion yuan in 2025, 4.95 billion yuan in 2026, and 5.64 billion yuan in 2027, with a year-on-year growth of 9.3% expected in 2025 [6][10] - The net profit is projected to be 826 million yuan in 2024, 753 million yuan in 2025, 866 million yuan in 2026, and 1.08 billion yuan in 2027, with a year-on-year growth of 15% expected in 2026 [6][10] - The gross margin is expected to be 43.2% in 2024, 41.3% in 2025, 43.1% in 2026, and 44.6% in 2027 [6][10] Segment Performance - The company's heparin raw material revenue was 291 million yuan in the first half of 2025, down 45% year-on-year, while the formulation revenue was 1.66 billion yuan, up 7% year-on-year, with the U.S. formulation platform Meitheal generating 1.14 billion yuan, a 20% increase [7][8] - The company has increased its R&D investment to 433 million yuan in the first half of 2025, accounting for 21.85% of revenue, which is a 126.55% increase year-on-year [7][8] Strategic Focus - The company is concentrating on overseas formulation sales and expects biosimilars to provide a new growth curve, maintaining its "Recommended" rating despite slight underperformance in the first half of 2025 [7][8]

Core Viewpoint - The recent financial report of Jianyou Co., Ltd. (603707) indicates a decline in both revenue and net profit for the first half of 2025 compared to the previous year, raising concerns about the company's financial health and operational efficiency [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 1.98 billion yuan, a decrease of 7.6% year-on-year [1]. - Net profit attributable to shareholders was 286 million yuan, down 29.32% from the previous year [1]. - In Q2 2025, total revenue was 1.095 billion yuan, reflecting a year-on-year decline of 3.84% [1]. - Q2 net profit attributable to shareholders was 202 million yuan, a decrease of 11.53% year-on-year [1]. - The gross margin was 37.49%, down 6.83% year-on-year, while the net margin was 14.46%, down 23.51% [1]. - The total of selling, administrative, and financial expenses reached 350 million yuan, accounting for 17.68% of total revenue, an increase of 54.56% year-on-year [1]. Key Financial Ratios - The company's return on invested capital (ROIC) for the previous year was 10.39%, indicating average capital returns [3]. - The historical median ROIC since the company went public is 14.31%, with a significant drop to -1.55% in the worst year, 2023 [3]. - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 96.18% [3]. - The debt situation is also a concern, with interest-bearing debt ratio reaching 20.97% [3]. - Accounts receivable to profit ratio has reached 154.56%, indicating potential collection issues [3]. Market Sentiment and Fund Holdings - Analysts expect the company's performance in 2025 to reach 1.023 billion yuan, with an average earnings per share of 0.63 yuan [3]. - The company is held by a prominent fund manager, Chen Hao from E Fund, who has recently increased his holdings [3][4]. - The largest fund holding Jianyou shares is the Jiaoyin Growth Mixed Fund, with a scale of 1.719 billion yuan and a recent net value increase of 0.16% [5].

Group 1 - The board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. held its 14th meeting of the 5th session on August 28, 2025, with 5 out of 6 directors present [1][2] - The meeting was chaired by Chairman Tang Yongqun and complied with relevant laws and regulations [1] - The board approved the half-year report for 2025 and its summary, which was previously reviewed by the audit committee [1][2] Group 2 - The board also approved a change in accounting policies, which was also reviewed by the audit committee prior to the meeting [2] - The voting results for both resolutions were unanimous, with 6 votes in favor and no votes against or abstaining [2]

Meeting Details - The fifth meeting of the supervisory board of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. was held on August 28, 2025, with a notification sent on August 18, 2025 [1] - The meeting was attended by 2 out of 3 supervisors, with one supervisor represented by proxy [1] Resolutions Passed - The supervisory board approved the half-year report for 2025, ensuring that the report does not contain any false records, misleading statements, or significant omissions [1][2] - The board also approved a change in accounting policy aimed at improving the alignment of revenue recognition criteria with the ERP information management system, ensuring more reliable and accurate financial information [2]